Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...

State and local public health officials in Kansas are responding to a tuberculosis (TB) outbreak in the Kansas City area, ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Chronic pain is a common complaint among those with COPD. Columnist Caroline Gainer shares the pain relief strategies that ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...